Clinical trial
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
NCT00419770 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Other · Completed
Key facts
| NCT number | NCT00419770 |
|---|---|
| Title | The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study |
| Official title | The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study |
| Lead sponsor | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Other |
| Collaborators | Gilead Sciences Industry Astellas Pharma Inc Novartis |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mucormycosis |
| Intervention type | Drug |
| Interventions | deferasirox, Placebo, Liposomal amphotericin B |
| Enrollment | 20 |
| Start date | Oct 1, 2007 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2010 |
| First posted | Jan 9, 2007 |
| Last update posted | Oct 16, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: